<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726490</url>
  </required_header>
  <id_info>
    <org_study_id>E16008</org_study_id>
    <nct_id>NCT02726490</nct_id>
  </id_info>
  <brief_title>Glyburide vs Glucovance in the Treatment of GDM</brief_title>
  <acronym>GGIG</acronym>
  <official_title>Glyburide vs Glucovance in the Treatment of Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center, El Paso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center, El Paso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management&#xD;
      of diabetes in pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized open label trial of glyburide compared to glucovance in the&#xD;
      management of gestational diabetes. We hypothesize that glucovance will provide improved&#xD;
      glycemic control and a lower failure rate with no increase in neonatal adverse outcomes.&#xD;
      Sixty-seven patients will be randomized by computer to each arm of the study. Outcomes will&#xD;
      be glycemic control, failure rate of the drug to achieve glycemic goals, and neonatal&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Recruitment&#xD;
  </why_stopped>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">August 14, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of glyburide compared to glucovance</measure>
    <time_frame>during the index pregnancy</time_frame>
    <description>failure rate of glyburide compared to glucovance in ability to achieve euglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maternal hypoglycemia</measure>
    <time_frame>during the index pregnancy</time_frame>
    <description>the rate of maternal hypoglycemia associated with each drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal birthweight</measure>
    <time_frame>at birth</time_frame>
    <description>infant weight at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal apgar scores</measure>
    <time_frame>at birth</time_frame>
    <description>infant 1 minute and 5 minute apgar scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal admission to the newborn intensive care unit (NICU)</measure>
    <time_frame>at birth or within the first 24 hours after birth</time_frame>
    <description>admission to the Newborn intensive care unit (NICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>up to 24 hours after delivery</time_frame>
    <description>failure of the neonate to maintain blood glucose &gt; 60 milligrams/deciliter (mg/dl)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.&#xD;
The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.&#xD;
The dose of glyburide will be increased as needed to a maximum of 20mg /day.&#xD;
Antenatal testing will be initiated at 28 weeks&#xD;
Patients will receive monthly growth scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucovance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.&#xD;
The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.&#xD;
Patients will receive monthly growth scans&#xD;
Antenatal testing will be initiated at 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)</description>
    <arm_group_label>Glyburide</arm_group_label>
    <other_name>micronase</other_name>
    <other_name>diabeta</other_name>
    <other_name>glynase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucovance</intervention_name>
    <description>glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)</description>
    <arm_group_label>Glucovance</arm_group_label>
    <other_name>combination glyburide and metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational diabetes&#xD;
&#xD;
          -  Pregnancy &gt; 12 weeks gestation&#xD;
&#xD;
          -  Ability to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to consent to the study&#xD;
&#xD;
          -  Pre-existing diabetes&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Serum creatinine &gt;1&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Allergy to sulfa;&#xD;
&#xD;
          -  Allergy to glyburide;&#xD;
&#xD;
          -  Allergy to metformin;&#xD;
&#xD;
          -  Fetal anomalies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa E Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech Health Sciences Center El Paso</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TTUHSC El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA, Morrison JC. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med. 2007 Nov;52(11):1011-5.</citation>
    <PMID>18161398</PMID>
  </reference>
  <results_reference>
    <citation>Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010 Jan;115(1):55-59. doi: 10.1097/AOG.0b013e3181c52132.</citation>
    <PMID>20027034</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gestational diabetes, pregnancy, diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02726490/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

